Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Neurol

Search In Journal Title:

Abbravation: Journal of Neurology

Search In Journal Abbravation:

Publisher

Springer Berlin Heidelberg

Search In Publisher:

DOI

10.1007/bf02925956

Search In DOI:

ISSN

1432-1459

Search In ISSN:
Search In Title Of Papers:

Detailing intralesional venous lumen shrinking in

Authors: Katharina Müller Joseph Kuchling Jan Dörr Lutz Harms Klemens Ruprecht Thoralf Niendorf Jens Wuerfel Friedemann Paul Tim Sinnecker
Publish Date: 2014/08/14
Volume: 261, Issue: 10, Pages: 2032-2036
PDF Link

Abstract

Intralesional venous lumen shrinking detectable by MRI was suggested as an in vivo marker of inflammation in multiple sclerosis MS In our study mean diameters of pre post and intralesional venous sections were determined in 49 patients with MS or clinically isolated syndrome CIS using a pixelwise analysis on susceptibilityweighted fluidattenuated inversion recovery sFLAIR images and T2weighted T2w imaging at 7 Tesla T We observed posttointralesional venous lumen shrinking on T2w images p = 0036 in an analysis of 338 venous sections Pretointralesional venous lumen reduction was only detectable in less than 50  of lesions and failed statistical significance when analysing T2w p = 0325 and sFLAIR images p = 0258 In conclusion thinning of intralesional veins in MS is—if detectable at all—probably less severe than previously reported and affects only a minority of MS lesionsThis work was supported by the German Research Foundation DFG Exc 257 We like to thank Alexander Brandt for statistical support and our technicians and study nurses Antje Els Susan Pikol Cynthia Kraut and Gritt Stoffels for technical support and other assistance This work was supported by the German Research Foundation DFG Exc 257 and by a restricted research grant from TEVA Pharma GermanyKM has nothing to disclose JK has nothing to disclose JD receives research grants from Novartis and Bayer and has received travel support from Novartis and Bayer Honoraria for consultancy from Bayer Genzyme and Teva and speaker honoraria from Bayer Teva Genzyme and Novartis CFP has received travel grants from Teva LH has received speaker honoraria from Biogen Idec Bayer Novartis and MerckSerono He serves on the advisory board for Biogen Idec Novartis Genzyme and TEVA and has received travel support from TEVA MerckSerono and Biogen Idec KR received research support from Novartis as well as speaking fees and travel grants from Bayer Healthcare Biogen Idec Merck Serono Sanofi/Genzyme Teva and Novartis and is supported by the German ministry of education and research BMBF/KKNMS Competence Network Multiple Sclerosis TN is founder of MRITOOLS GmbH Berlin Germany and received speaker honoraria from Siemens Healthcare Erlangen Germany FP has received speaker honoraria travel grants and research grants from Teva/Sanofi Bayer MerckSerono Biogen Idec and Novartis FP is supported by the German Research Foundation Exc 257 and by the German ministry of science BMBF/KKNMS and has received travel reimbursement from the Guthy Jackson Charitable Foundation TS received a travel grant from Bayer Genzyme—a Sanofi company and Novartis JW served for Novartis and BiogenIdec advisory boards received a Novartis research grant and speaker honoraria from Bayer Novartis and BiogenIdec He is supported by the German ministry of science BMBF/KKNMS On behalf of all authors the corresponding author states that there is no conflict of interest

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Toothbrushing-induced seizures at onset of cryptogenic partial epilepsy: a case report
  2. Associated and predictive factors of depressive symptoms in patients with Parkinson’s disease
  3. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy
  4. Walter Rudolf Hess (1881–1973)
  5. Current concepts and future approaches to vestibular rehabilitation
  6. Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson’s disease
  7. Vestibular animal models: contributions to understanding physiology and disease
  8. Primary leptomeningeal lymphoma of the cauda equina: a rare cause of radiculopathy
  9. DWI and FLAIR imaging in herpes simplex encephalitis: a comparative and topographical analysis
  10. Interferon beta in secondary progressive multiple sclerosis
  11. Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity
  12. Diaphragm of the internal carotid artery: a novel cause of pulsatile tinnitus
  13. Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry
  14. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma
  15. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma
  16. Neurological complications of Behçet’s syndrome
  17. Highly skewed inactivation of the wild-type X-chromosome in asymptomatic female carriers of spinal and bulbar muscular atrophy (Kennedy’s disease)
  18. Meningitis–retention syndrome
  19. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score
  20. Early MRI findings in Creutzfeldt-Jakob disease
  21. Causes and characteristics of horizontal positional nystagmus
  22. The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson’s disease
  23. Mastication-induced vertigo and nystagmus
  24. Need for extensive diagnostic work-up for patients with lacunar stroke
  25. Low testosterone and myasthenia gravis in males: a national record-linkage study
  26. Plasma levels of nitric oxide and stroke outcome
  27. High field MR imaging and 1 H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis
  28. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse
  29. Cesare Vigna (1819–1892)
  30. Cesare Vigna (1819–1892)
  31. Aquaporin-4 seropositivity in a patient with coeliac disease but normal neurological examination and imaging
  32. Repetitive magnetic stimulation A novel therapeutic approach for myofascial pain syndrome
  33. Downbeat positioning nystagmus is a common clinical feature despite variable phenotypes in an FHM1 family
  34. Psychological interventions for migraine: a systematic review
  35. Respiratory dysfunction in Charcot–Marie–Tooth disease type 1A
  36. Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation
  37. Epiretinal membrane: a treatable cause of visual disability in myotonic dystrophy type 1
  38. Spinocerebellar ataxia type 17 in a patient from an Indian kindred
  39. ‘Switching off’ SUNCT by sudden head movement: a new symptom
  40. A clinical, radiological and outcome study of status epilepticus from India
  41. The impact of subthalamic deep brain stimulation on caregivers of Parkinson’s disease patients: an exploratory study
  42. Management of respiratory symptoms in ALS
  43. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease
  44. Opsoclonus–myoclonus–ataxia syndrome and HIV seroconversion
  45. Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study
  46. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci
  47. Presenilin 2 mutation R71W in an Italian early-onset sporadic Alzheimer’s disease case
  48. Recovery from mild traumatic brain injury
  49. Modafinil for Parkinson’s disease fatigue
  50. Diagnosis and treatment of upper limb apraxia
  51. Familial aggregation in atypical Parkinson’s disease: a case control study in multiple system atrophy and progressive supranuclear palsy
  52. Thymectomy: role in the treatment of myasthenia gravis
  53. Long-term EMG recordings differentiate between parkinsonian and essential tremor
  54. Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies
  55. Cortical thinning in drug-naive Parkinson’s disease patients with depression
  56. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease
  57. Frontal lobe function and behavioral changes in amyotrophic lateral sclerosis: a study from Southwest China
  58. Tic disorders: from pathophysiology to treatment
  59. Parkinson’s disease: news on tremor, subthalamic stimulation and impulse control disorders
  60. The use of multiattribute decision models in evaluating triptan treatment options in migraine
  61. Psychiatric disorders in idiopathic-isolated focal dystonia
  62. Domain-specific versus generalized cognitive screening in acute stroke
  63. Multiple sclerosis imaging: recent advances
  64. Hemifacial presentation of mitochondrial myopathy
  65. Teleneurology in stroke management: costs of service in different organizational models
  66. Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS
  67. Cerebral blood flow abnormalities in patients with neurally mediated syncope
  68. Specific electron transport chain abnormalities in amyotrophic lateral sclerosis
  69. Parkinson’s disease-related disorders in the impulsive-compulsive spectrum
  70. Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients’ perspectives
  71. Bladder dysfunction in subacute combined degeneration
  72. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis
  73. Missense exchanges in the TTBK2 gene mutated in SCA11
  74. Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1
  75. Prior medical conditions and the risk of amyotrophic lateral sclerosis
  76. An epidemiological study of neuromyelitis optica in Cuba
  77. Brachial neuritis caused by varicella-zoster diagnosed by changes in brachial plexus on MRI
  78. Subthalamic nucleus stimulation in Parkinson’s disease
  79. Dopaminergic medication does not improve stepping responses following backward and forward balance perturbations in patients with Parkinson’s disease
  80. Novel EXOSC3 mutation causes complicated hereditary spastic paraplegia
  81. A genome wide linkage disequilibrium screen in Parkinson’s disease
  82. Differential effect of Huntington's and Parkinson's diseases in programming motor sequences of varied lengths
  83. Accuracy of subjective and objective handwriting assessment for differentiating Parkinson’s disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study
  84. The utility of F wave chronodispersion in lumbosacral radiculopathy
  85. Accuracy of subjective and objective handwriting assessment for differentiating Parkinson’s disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study
  86. Recurrent rhabdomyolysis due to muscle β-enolase deficiency: very rare or underestimated?
  87. Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else?
  88. Paroxysmal raised intracranial pressure associated with spinal meningeal cysts
  89. The relationship between impairment of voluntary movements and cognitive impairment in Huntington’s disease
  90. Long-term domain-specific improvement following poor grade aneurysmal subarachnoid hemorrhage
Search Result: